What AdjuCor does

AdjuCor GmbH is a Munich-based, privately held medical device company founded in 2012 by cardiothoracic surgeon Prof. Stephen Wildhirt. The company is developing a single platform product, reBEAT, a biventricular mechanical circulatory support device intended for patients with advanced heart failure awaiting heart transplantation or in need of temporary circulatory support. reBEAT works by applying synchronized pulsatile force from the epicardium (outside the heart) without making any contact with blood, and is implanted minimally invasively on the beating heart without sutures. The product is positioned as a differentiated alternative to existing blood-contacting ventricular assist devices (VADs), with claims of reduced stroke and bleeding risk, shorter procedure times, and faster patient mobilization.

The underlying technology platform combines a patented extravascular architecture with patient-specific design; AdjuCor is also developing 3D-printable biomimetic polymers through the BMBF-funded PolyKARD consortium (Fraunhofer IAP, NMI, pro3dure medical, Young Optics) to enable customized implants. The company has built a clinical evidence base including a 60-day chronic animal survival study and the world's first-in-human trial of an extravascular biventricular cardiac assist device, completed in 2025 with results published in JACC: Basic to Translational Science. Strategic clinical partners include Hannover Medical School (first-in-human site, with Prof. Arjang Ruhparwar as clinical advisor) and Royal Brompton and Harefield Hospitals (with Prof. Ulrich Stock as clinical advisor).

The business model is pre-commercial: reBEAT is currently used exclusively in clinical investigations and is not yet available for sale. Revenue mechanics will ultimately rest on direct hospital and cardiac surgery center sales of the implantable hardware, supplemented by potential licensing of the underlying non-blood-contacting technology. Capital structure to date reflects this stage: cumulative disclosed funding exceeds €44.5 million across private investors, the European Innovation Council (including a €29M Series B in June 2021 and a €2.5M EIC Accelerator grant in June 2022), and German federal and Bavarian government entities. GTM motion is enterprise field sales into cardiac surgery centers, layered with conference-led KOL engagement (ISHLT, AATS). The company employs 40+ staff across development, manufacturing, clinical, and support functions and is preparing for a US clinical study as the next major milestone.

Name

AdjuCor

Legal name

AdjuCor GmbH

Website

https://adjucor.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

AdjuCor GmbH is a Munich-based medical device company developing reBEAT, a biventricular, epicardial mechanical circulatory support device that avoids blood contact. It is intended for advanced heart failure patients awaiting heart transplantation, currently in clinical investigation and not yet commercially available.

Ownership category

akta.pro rank

Product category

Cardiac Assist Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Cardiac assist devices
• Mechanical circulatory support
• Ventricular assist technology
• Heart failure treatment
• Extravascular heart pump

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

1. Medical Device Sales: Sale of the reBEAT cardiac support device to hospitals and cardiac surgery centers. Currently exclusively used in clinical investigations and not yet available for sale.
2. Technology Licensing: Potential licensing of proprietary technology and patents related to non-blood-contacting cardiac support systems.
3. Grant Funding: Non-dilutive funding from European Union, German federal government (BMBF), and Bavarian provincial government for research and development activities.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

AdjuCor develops and is commercializing the reBEAT system, a biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to support pump function without any blood contact, targeting patients with advanced heart failure awaiting transplantation. The product is currently in clinical investigation phase and not yet available for commercial sale.

Product overview

AdjuCor operates as a single-product company focused exclusively on the reBEAT system — a biventricular, minimally invasive, epicardial cardiac support device that provides mechanical circulatory support without blood contact. The company's entire portfolio centers on this one technology platform, which works by applying synchronized pulsatile force from the epicardium to support one or both ventricles of the failing heart. The product is currently in clinical investigation phase and not yet available for commercial sale.

Differentiator

Problem solved

Functional benefit

Brands

• reBEAT: A biventricular cardiac support device - a minimally invasive, epicardial mechanical circulatory support technology designed to assist one or both ventricles of the failing heart without blood contact.

Products and services

• reBEAT Cardiac Support System A biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to assist pump function without any blood contact. It is designed for patients with advanced heart failure awaiting transplantation, supporting one or both heart chambers with patient-specific adjustable energy transfer.

Quantifiable outcome

• Reduced stroke and bleeding risk compared to blood-contacting devices
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Fraunhofer Institute for Applied Polymer Research IAPcoreStrategic or Co-development Partner · 4 February 2020PolyKARD project partner developing 3D printable biomimetic polymers that mimic properties of the pericardium for customized implants.
• NMI Natural and Medical Sciences InstitutecoreStrategic or Co-development Partner · 4 February 2020PolyKARD project partner testing polymers for in vitro cytotoxicity and processing using 3D printing methods and electrospinning.
• pro3dure medical GmbHminorStrategic or Co-development Partner · 4 February 2020PolyKARD project partner establishing upscaling process of photopolymers and resin synthesis under GMP guidelines.
• Young Optics Europe GmbHminorStrategic or Co-development Partner · 4 February 2020PolyKARD project partner developing 3D printing system for production of class III medical products with complete traceability.
• VDI Verein Deutscher Ingenieure e.V.minorImplementation/ SI/ Consulting Partner · 4 February 2020Project management agency for PolyKARD project on behalf of BMBF.
• Technical University of Munich (TUM)coreStrategic or Co-development PartnerAcademic partner providing research collaboration and clinical expertise in cardiac surgery and heart failure treatment.
• Ludwig Maximilian University of Munich (LMU)coreStrategic or Co-development PartnerAcademic partner for cardiac research and development collaboration.
• Hochschule München (HSM)minorStrategic or Co-development PartnerUniversity partner for applied research in medical device development.
• Hannover Medical School (MHH)coreStrategic or Co-development PartnerClinical partner for first-in-human trial of reBEAT. Prof. Arjang Ruhparwar serves on Clinical Advisory Board.
• Royal Brompton and Harefield HospitalscoreStrategic or Co-development PartnerClinical advisor Prof. Ulrich Stock provides consultation on cardiac surgery and heart failure treatment using reBEAT.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• FineHeart: French medtech developing a novel, fully implantable cardiac assist device (ICOMS) targeting advanced heart failure. Closest comparable to AdjuCor's reBEAT as another next-generation, minimally invasive cardiac assist platform pursuing a differentiated non-LVAD architecture.
• CorWave: French medtech developing a next-generation LVAD based on a biomimetic wave-membrane pump producing pulsatile flow. Directly comparable to AdjuCor as a developer of novel mechanical circulatory support technology targeting improved physiologic blood flow versus continuous-flow LVADs.

Broad incumbents

• Abbott: Global medtech leader and maker of HeartMate 3, the dominant durable LVAD in clinical use. Direct incumbent in mechanical circulatory support; AdjuCor's reBEAT is positioned as a differentiated alternative to Abbott's blood-contacting LVAD platform.
• Medtronic: Global medtech incumbent that previously marketed the HVAD system (discontinued in 2021). Broad incumbent in cardiac surgery and heart failure with deep clinical relationships; a credible strategic acquirer of novel MCS technologies like AdjuCor's.
• Abiomed (Johnson & Johnson MedTech): Acquired by Johnson & Johnson MedTech, Abiomed is the leader in percutaneous ventricular assist devices (Impella) used in high-risk PCI and cardiogenic shock. Broad incumbent in mechanical circulatory support with overlapping customer base of cardiac surgeons and interventional cardiologists.

Emerging players

• Calon Cardio: UK-based early-stage company developing miniVAD, a fully implantable, miniature ventricular assist device. Comparable emerging player pursuing miniaturized, less-invasive mechanical circulatory support targeting the same advanced heart failure population.
• CARMAT: French medtech developing the Aeson total artificial heart for patients with end-stage biventricular heart failure. Comparable emerging player addressing advanced heart failure, though with a different modality (full heart replacement vs. assist).
• Evaheart: US/Japanese company developing the EVAHEART continuous-flow LVAD system. Comparable emerging player in mechanical circulatory support pursuing long-term destination therapy in the same advanced heart failure market.
• SynCardia Systems: Maker of the temporary Total Artificial Heart (TAH) used as a bridge to transplant. Comparable emerging player targeting the same advanced heart failure / transplant-bridge patient population, though using a different therapeutic modality.
• Procyrion: US-based developer of Aortix, a percutaneous mechanical circulatory support device. Comparable emerging player pursuing novel, less-invasive circulatory support platforms relevant to the heart failure treatment paradigm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AdjuCor